Early pharmacogenicity evaluation is the pharmacodynamic study, pharmacokinetic properties and safety evaluation of lead molecules in the drug development process- The purpose of this preliminary evaluation is to determine whether these lead molecules have the potential to be developed as drugs- By evaluating the pharmacability ability of lead molecules at the earliest opportunity, pharmaceutical companies can select candidates with good pharmacability prospects that require a reduced investment and can be developed at the fastest possible time- They can then implement further development or terminate the follow-up research and development of drugs with poor prospects at an early stage- This improves the success rate of new drug development and reduces research and development costs.
In response to the evolving industry landscape and shifting market demands, InnoSar has strategically pivoted towards offering early pharmaceutical services that are both timely and convenient for drug development- The company's expertise lies in its highly specialised pharmacodynamic, pharmacokinetic and early toxicology research teams and platforms, which have been developed to facilitate the expedited progression of client research projects